Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwh...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。